Eindhoven's Catharina Hospital Purchases ViewRay’s MRIdian Linac

December 21, 2020

Leading Clinical Training Hospital Aims to Begin MRIdian Patient Treatments in 2021

CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.

Catharina Hospital is the largest hospital in the Eindhoven region and a top clinical training facility. It's focused on providing patients with the best care every day with leading experience in cardiovascular care and oncology. Many regional and national hospitals refer patients to Catharina Hospital for their renowned expertise in these areas.

"We believe adding MRIdian to our extensive portfolio of cancer treatments will improve the quality of care we can provide for our patients. Through the use of MR-guidance and on-table adaptive capabilities, we can improve the accuracy with which we deliver radiation, deliver higher doses in less treatment sessions, and reach tumors that were otherwise virtually unreachable," said Peter-Paul van der Toorn, leading radiation oncologist at Catharina Hospital.

"MRI-guided radiation therapy is rapidly evolving, and we look forward to collaborating with ViewRay in future technology developments and advance the practice of MRI-guided radiation therapy," said Coen Hurkmans, leading clinical physicist at Catharina Hospital.

Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system delivers ablative, high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.

"We're pleased to welcome Catharina Hospital to our family of centers integrating MRIdian into their radiation oncology program," said Paul Ziegler, Senior Vice President of Sales and Marketing at ViewRay. "They have a proven clinical pedigree in effectively treating historically difficult to treat tumors and we believe MRIdian will be the perfect complement to that expertise."

Currently 40 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 11,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/mridian-locator.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's anticipated future operating and financial performance, and ViewRay's conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.